louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06185218: Different Injection Site Maps & Intravesical Botulinum Toxin
Official title: The Effect of Different Injection Site Maps on Intravesical Botulinum Toxin of Bladder
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Bladder Disease
Keywords: Botulinum Toxin
overactive bladder
interstitial cystitis
Lead sponsor: Başakşehir Çam & Sakura City Hospital
Sponsor class: OTHER_GOV
First posted: 2023-12-29
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Botulinum toxin injection into the bladder is used in current practice in urological diseases such as overactive bladder or interstitial cystitis. As far as is known, botulinum toxin injection sites have not been clearly defined. In this study, investigators are planning to compare botulinum toxin effectiveness with different injection site maps.


Eligibility criteria: Inclusion Criteria:

* Older than 18 years
* Interstitial cystitis patients
* Overactive bladder

Exclusion Criteria:

* younger than 18 years

Primary outcomes:
measure: Overactive bladder-V8 questionnaire will be used for efficacy of treatment.
timeFrame: Estimated 1 month for every patient after treatment.
measure: Urodynamics test will be assessed for efficacy of treatment.
timeFrame: Estimated 1 month for every patient after treatment.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06363318: Comparison of Open and Laparoscopic Appendectomy in Pediatric Population
Official title: Comparison of Open and Laparoscopic Appendectomy in Pediatric Population
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Appendicitis Acute
Keywords: Appendicitis
children
laparoscopic appendectomy
open appendectomy
Lead sponsor: King Edward Medical University
Sponsor class: OTHER
First posted: 2024-04-12
Enrollment: 100
Sex: ALL
Minimum age (years): 7
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: children were randomly divided in two groups. In group A, laparoscopic appendectomy was done. In group B, open appendectomy was done
Primary purpose: TREATMENT

Brief summary: Introduction: In the era of minimally invasive surgery, changing trends are towards laparoscopic surgery, first introduced in 1983. Now the preferred operation for children with appendicitis, laparoscopic appendectomy is associated with a reduced risk of wound infection, less postoperative pain and shorter hospital stay as compared to open appendectomy.

Objectives: To compare the outcome of open and laparoscopic appendectomy in children presenting with appendicitis in terms of operative time, postoperative pain, wound infection and hospital stay.

Detailed description: A total of 100 children presenting with acute appendicitis were included in this study, In group A, patients were undergone laparoscopic appendectomy.

In group B, patients were undergone open appendectomy. During surgery, operative time was noted. After surgery, patients were shifted to surgical wards and were followed-up there till discharge. Patients were followed regularly by the researcher for mean post-operative pain at 24 hours. At discharge, hospital stay was noted. Then patients followed up in outpatient department for 10 days for any evidence of wound infection.

Eligibility criteria: Inclusion Criteria:

1. Children of age 7-12 years of either gender diagnosed as acute appendicitis
2. pediatric appendicitis score \>4

Exclusion Criteria:

1. Children with comorbidities,
2. Perforated appendix
3. Appendicular mass (on clinical examination). -

Primary outcomes:
measure: Operative time
timeFrame: during surgery
measure: wound infection
timeFrame: 10 days
measure: Hospital stay
timeFrame: 5 days
measure: Postoperative pain
timeFrame: 48 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Muhammad Sharif
state: Punjab
Study officials:
affiliation: King edward Medical University/Mayo Hospital Lahore
name: Muhammad Sharif, FCPS
role: STUDY_CHAIR
References:
Clinical trial NCT04115618: SIB in Upper Thoracic Esophageal Squamous Cell Carcinoma
Official title: Simultaneous Integrated Boost Intensity-modulated Chemoradiotherapy in Upper Thoracic Esophageal Squamous Cell Carcinoma: a Phase II Study of Single Institution
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Esophageal Squamous Cell Carcinoma
Keywords: esophageal cancer
Chemoradiotherapy
Simultaneous Integrated Boost Intensity
Lead sponsor: Fudan University
Sponsor class: OTHER
First posted: 2019-10-04
Enrollment: 65
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Using IMRT technology, two fields are irradiated synchronously, prescription radiation dose: 50.4 Gy/28F in PTV-C, 1.8 Gy per fraction; 63 Gy/28F in PTV-G, 2.25 Gy per fraction. Six times of concurrent DP week regimen chemotherapy: cisplatin 20mg/m2 qw plus docetaxel 20mg/m2 qw.
Primary purpose: TREATMENT

Brief summary: This study was designed to predict the toxicity and efficacy of Simultaneous Integrated Boost Intensity-modulated Chemoradiotherapy in Upper Thoracic I-IVA Esophageal Squamous Cell Carcinoma.


Eligibility criteria: Inclusion Criteria:

1. Histological or cytologic diagnosis of esophageal squamous carcinoma;
2. Aged 18-75 years;
3. KPS ≥ 70;
4. Upper thoracic esophageal squamous carcinoma: the upper margin of the lesion is located between the entrance of esophagus and the inferior edge of the azygos vein;
5. Stage I-IVA(AJCC 6th,2009);
6. Not able to be surgically resection or rejected;
7. Not have received any prior anticancer therapy;
8. No serious system dysfunction and immuno-deficiency, Adequate organ function including the following: Hemoglobin ≥9 g/dL, WBC≥4x109/L, Neutrophils (ANC )≥1.5x10\^9/L, platelet count ≥100x 10\^9/L, serum creatinine\<1.5 mg/dL,urea nitrogen \<8 mmol/L;
9. No history of malignancy;
10. No perforation of esophagus, no deep ulcer of esophagus;
11. Joined the study voluntarily and signed informed consent form.

Exclusion Criteria:

1. Pregnant or breast-feeding women or people during the birth-period who refused to take contraceptives;
2. Patient who has metastasis such as lung, liver metastasis;
3. Other malignant tumors;
4. Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior;
5. Uncontrollable heart disease, diabetes and hypertension, pulmonary fibrosis, and chest confirmed active pulmonary inflammation require antibiotic treatment, as well as superior vena cava compression syndrome;
6. After surgery, exploratory thoracotomy, radiotherapy, chemotherapy, or targeting therapy;
7. Combination of pure red cell anemia or gamma globulin;
8. Allergic to any medication component studied.

Primary outcomes:
measure: Toxicity Effect
timeFrame: 8 Weeks
Secondary outcomes:
measure: PFS
timeFrame: One month
measure: OS
timeFrame: One month
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
state: Shanghai
Study officials:
References:
Clinical trial NCT05618418: BActeriophages To Treat Liver Disease Eliminating Harmful Bacteria (BATTLE)
Official title: BActeriophages To Treat Liver Disease Eliminating Harmful Bacteria (BATTLE)
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Alcoholic Hepatitis
Keywords: Gut microbiome
Lead sponsor: Copenhagen University Hospital, Hvidovre
Sponsor class: OTHER
Collaborators: name: Copenhagen University Hospital at Herlev
First posted: 2022-11-16
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hospital admitted patients with alcoholic hepatitis

Brief summary: Alcoholic hepatitis is a disease with a high mortality rate with few treatment options improving survival. Recently certain bacterial strains has been correlated to survival in patients with alcoholic hepatitis.

In the BATTLE-trial the investigators will investigate if certain bacteria are correlated to decreased chance of survival in patients with alcoholic hepatitis.

Detailed description: Patients with alcoholic hepatitis who are admitted to Copenhagen University Hospital Hvidovre and Herlev will be invited to participate.

Blood and fecal samples following hospital admission will be collected. Through one-year follow-up correlation of certain bacteria in fecal samples with survival will be investigated.

In particular whether patients with cytolysin producing E. faecalis has a decreased chance of survival compared to patients without this bacteria.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18
* Bilirubin \> 50 micromol/L
* History of large alcoholic consumption in period prior to hospital admission (in the last six months)
* No bile-duct obstruction (investigated through US, CT og MRI)

Exclusion Criteria:

* Hepatocellulary carcinoma
* Viral hepatitis
* Autoimmune hepatitis
* Portal vein thrombosis
* Pregnancy
* Expected survival for less than one year caused by other diseases (based on decision from project responsible doctors

Primary outcomes:
measure: Survival in patients with and without cytolysin producing E. faecalis in fecal samples
timeFrame: 6 months
Secondary outcomes:
measure: Survival in patients with and without cytolysin producing E. faecalis in fecal samples
timeFrame: 1 year
measure: Survival in patients with and without cytolysin producing E. faecalis in fecal samples
timeFrame: 30 days
measure: Survival in patients with and without cytolysin producing E. faecalis in fecal samples
timeFrame: 90 days
Other outcomes:
Locations:
city: Hvidovre
country: Denmark
facility: Copenhagen University Hospital Hvidovre
Study officials:
affiliation: Copenhagen University Hospital, Hvidovre
name: frederik cold, MD, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01258218: Accent MRI Pacemaker and Tendril MRI Lead New Technology Assessment
Official title: Accent MRI Pacemaker and Tendril MRI Lead New Technology Assessment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Bradycardia
Lead sponsor: Abbott Medical Devices
Sponsor class: INDUSTRY
First posted: 2010-12-10
Enrollment: 78
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with approved Class I or Class II indication per ESC guidelines for implantation of a dual chamber pacemaker or single chamber pacemaker.

Brief summary: The intent of this study is to evaluate the performance of the implanted Accent MRI TM system in a clinical setting and optionally in the MRI environment. This system includes the St. Jude Medical Tendril MRI™ lead and SJM Accent MRITM DR pacemaker. Also the MRI Activator™ will be evaluated in this study. The MRI Activator is a handheld device that allows the user to enable and disable MRI Settings as well as check the status of MRI Settings in the pacemaker. The patient population under study includes patients with a standard bradycardia pacing indication.


Eligibility criteria: Inclusion Criteria:

* Approved Class I or Class II indication per ESC guidelines for implantation of a dual chamber pacemaker or single chamber pacemaker.
* Receiving a new Accent MRITM pacemaker and Tendril MRI™ lead (either initial implant or complete system change out with no abandoned devices).
* Ability to provide informed consent for study participation.
* Is willing and able to comply with the prescribed follow-up tests and schedule of evaluations.

Exclusion Criteria:

* Have an existing pacemaker or ICD (abandoned devices and/or leads are not allowed. A new pacemaker and lead or complete system change out is required for enrollment).
* Have an existing active/inactive implanted medical device (e. g., Neurostimulator, infusion pump, etc.).
* Have a non-MRI compatible device or material implant (e.g., intracranial aneurysm clip, non-MRI compatible devices or material, metals or alloys, etc.).
* Have a lead extender or adaptor.
* Have a mechanical, prosthetic or bioprosthetic tricuspid heart valve.
* Have an abdominal diameter (approximately \> 60cm) which results in contact with the magnet façade.
* Are currently participating in a study that includes an active treatment arm.
* Are pregnant or planning to become pregnant during the duration of the study.
* Have a life expectancy of less than 6 months due to any condition.
* Are less than 18 years of age.
* Are unable to comply with the follow up schedule.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Graz
country: Austria
Study officials:
References:
Clinical trial NCT01909518: Detection of Early Esophageal Squamous Neoplasia
Official title: Detection of Early Esophageal Squamous Neoplasia by Using Virtual Chromoendoscopy and Probe-based Confocal Laser Endomicroscopy
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Esophageal Squamous Intraepithelial Neoplasia
Keywords: Esophageal Squamous Intraepithelial Neoplasia
surface maturation scoring
probe-based confocal laser endomicroscopy
virtual chromoendoscopy
Lead sponsor: Shandong University
Sponsor class: OTHER
First posted: 2013-07-26
Enrollment: 200
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Consecutive patients screened that fulfill the eligibility criteria at Qilu Hospital, Shandong University will be enrolled into the study

Brief summary: The aim of the present study：

1. To investigate the diagnosing value of pCLE for early esophageal squamous neoplasia.
2. To assess the detection rate of early esophageal squamous neoplasia by virtual chromoendoscopy

Detailed description: Probe-based confocal laser endomicroscopy (pCLE; Cellvizio, Mauna Kea Technologies, Paris, France) is a newly developed endoscopic device and has shown its value for diagnosing Barrett's esophagus, colonal polyps and etc. However, none research has focus on early esophageal squamous neoplasia until now. Previous diagnosis of early esophageal neoplasia is based on the lugol staining which is time wasting and have many adverse events.Other researches have suggested virtual chromoendoscopys are beneficial for screening esophageal tumors. Therefore, the aim of the present study is 1.To investigate the diagnosing value of pCLE for early esophageal squamous neoplasia according to the surface maturation scoring(SMS) diagnostic criteria and 2. To assess the detection rate of early esophageal squamous neoplasia by virtual chromoendoscopy(I-SCAN).

Eligibility criteria: Inclusion Criteria:

* Patients aged between 50 and 80 years old
* Patients undergo screening endoscopy or histologically verified esophageal squamous intraepithelial neoplasia before.

Exclusion Criteria:

* Advanced esophageal, gastric or duodenal cancer
* History of upper GI tract surgery
* Coagulopathy or acute GI bleeding
* Pregnant or breast-feeding (for females)
* Impaired renal function
* Allergy to fluorescein sodium
* Inability to provide informed consent.

Primary outcomes:
measure: The diagnostic accuracy of pCLE on early esophageal squamous neoplasia
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
city: Jinan
country: China
facility: Department of Gastroenterology, Qilu Hospital, Shandong University
state: Shandong
Study officials:
affiliation: Qilu Hospital, Shandong University
name: Yanqing Li, MD. PhD.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01137318: Combined Cognitive Remediation and Behavioral Intervention for Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)
Official title: Combined Cognitive Remediation and Behavioral Intervention for Treatment of ADHD
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: ADHD
Keywords: ADHD
Impairment
Treatment
Cognitive Remediation
Behavioral Parent Training
Lead sponsor: Queens College, The City University of New York
Sponsor class: OTHER
First posted: 2010-06-04
Enrollment: 84
Sex: ALL
Minimum age (years): 7
Maximum age (years): 11
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is to evaluate a novel sequenced combination of a promising, computerized cognitive training program targeting working memory (WM) deficits in children with attention-deficit/hyperactivity disorder (ADHD) in combination with behavioral parent training, a well-established, evidence-based intervention for ADHD.

The combined active intervention, compared to the combined control intervention will result in improvement in primary psychosocial (i.e., parent/teacher reported child impairment; parental stress; parenting behavior; and observed child academic achievement) and psychiatric (parent/teacher rated ADHD, ODD, and CD symptoms; observed activity level and attention) outcomes at post-treatment and follow up assessment, with the combined active intervention resulting in greater improvements in these outcomes.


Eligibility criteria: Inclusion Criteria:

- Diagnosis of ADHD Children 7-11 year olds English Speaking

Exclusion Criteria:

- Pervasive Developmental Disorder IQ\< 80

Primary outcomes:
measure: ADHD Symptoms
timeFrame: 3 month follow up
measure: Impairment
timeFrame: 3 month follow up
measure: Academic Achievement
timeFrame: 3 month follow up
measure: ODD symptoms
timeFrame: 3 month follow up
measure: CD symptoms
timeFrame: 3 month follow up
measure: Motor Activity
timeFrame: 3 month follow up
measure: Inattention
timeFrame: 3 month follow up
measure: Impulsivity
timeFrame: 3 month follow up
measure: Parenting Behavior
timeFrame: 3 month follow up
measure: Parenting Stress
timeFrame: 3 month follow up
Secondary outcomes:
Other outcomes:
Locations:
city: Flushing
country: United States
facility: Queens College
state: New York
Study officials:
affiliation: Queens College, The City University of New York
name: Anil Chacko, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Chacko A, Bedard AC, Marks DJ, Feirsen N, Uderman JZ, Chimiklis A, Rajwan E, Cornwell M, Anderson L, Zwilling A, Ramon M. A randomized clinical trial of Cogmed Working Memory Training in school-age children with ADHD: a replication in a diverse sample using a control condition. J Child Psychol Psychiatry. 2014 Mar;55(3):247-55. doi: 10.1111/jcpp.12146. Epub 2013 Oct 7.
Clinical trial NCT01448018: Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion
Official title: Pilot Study on Efficacy and Tolerance of Intravitreous Injection of Ranibizumab (Lucentis®) in Early-onset Central Retinal Vein Occlusion in Comparison to Hemodilution Using Erythrocytapheresis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Central Retinal Vein Occlusion
Lead sponsor: Centre Hospitalier Intercommunal Creteil
Sponsor class: OTHER
First posted: 2011-10-06
Enrollment: 45
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare ranibizumab injection to hemodilution at the early phase of Central Retinal Vein Occlusion (CRVO) and to determine if the combination of both treatments may have a synergic effect.

Detailed description: Patients with recent-onset CRVO (lasting for less than 1 month)are randomly assigned to one of 3 groups: hemodilution using erythrocytapheresis alone, 3 monthly injection of ranibizumab alone, or both.

Patients are followed monthly during the 6-month study.

Eligibility criteria: Inclusion Criteria:

* CRVO confirmed by fluorescein angiography
* duration from onset of 1 month or less
* visual acuity of 20/32 or less

Exclusion Criteria:

* neovascular complication
* extensive retinal ischemia requiring prompt panretinal photocoagulation
* hematocrit level lower than 38%
* previous laser or surgery in the study eye, etc

Primary outcomes:
measure: Change in visual acuity
timeFrame: 6 months
Secondary outcomes:
measure: Gain in visual acuity of 2 ETDRS-lines or more
timeFrame: 6 months
Other outcomes:
Locations:
city: Creteil
country: France
facility: Intercommunal Hospital
city: Paris
country: France
facility: Pitie-Salpetriere Hospital
Study officials:
References:
citation: Glacet-Bernard A, Atassi M, Fardeau C, Romanet JP, Tonini M, Conrath J, Denis P, Mauget-Faysse M, Coscas G, Soubrane G, Souied E. Hemodilution therapy using automated erythrocytapheresis in central retinal vein occlusion: results of a multicenter randomized controlled study. Graefes Arch Clin Exp Ophthalmol. 2011 Apr;249(4):505-12. doi: 10.1007/s00417-010-1532-5. Epub 2010 Oct 17.
Clinical trial NCT04033718: Inpatient Package to Reduce HIV and AIDS-related Death in Zambia
Official title: Inpatient Package to Reduce HIV and AIDS-related Death in Zambia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV/AIDS
Transitions of Care
Hospitalization
Tuberculosis
HIV Testing
Cryptococcosis
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
Collaborators: name: University Teaching Hospital
name: University of Maryland
First posted: 2019-07-26
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Early post-discharge mortality is high among HIV-infected Zambians admitted to the hospital. Likely this is in part due to missed opportunities to identify lethal coinfections and optimize HIV care during admission (and before discharge). In this study the investigators will develop and pilot a new approach to inpatient HIV care that follows international guidelines for management of advanced HIV disease.


Eligibility criteria: Inclusion Criteria:

* 18+ years old
* HIV-positive (by self-report or DCT result in UTH file)
* Resident of Lusaka
* Admitted to the hospital

Exclusion Criteria:

* Too sick to provide informed consent (based on clinician opinion)
* Likely to be discharged in the next 48 hours (based on clinician opinion)

Primary outcomes:
measure: Coinfection diagnosis
timeFrame: Through hospital discharge, an average of 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Lusaka
country: Zambia
facility: University Teaching Hospital
Study officials:
affiliation: Assistant Professor of Medicine
name: Michael J Vinikoor, MD
role: PRINCIPAL_INVESTIGATOR
References: